Colla S - Search Results

1

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.

Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Colla S, et al. Cancer Cell. 2015 May 11;27(5):644-57. doi: 10.1016/j.ccell.2015.04.007. Cancer Cell. 2015. PMID: 25965571 Free PMC article.

2

Angiopoietins expression by human myeloma cells.

Colla S, Roti G, Rizzoli V, Giuliani N. Colla S, et al. Haematologica. 2003 Jun;88(6):ELT20; author reply ELT21. Haematologica. 2003. PMID: 12801859 No abstract available.

3

Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

Giuliani N, Colla S, Rizzoli V, Barillé-Nion S, Bataille R. Giuliani N, et al. Among authors: colla s. Cancer Res. 2004 Jan 15;64(2):772-3; author reply 774-5. Cancer Res. 2004. PMID: 14744797 No abstract available.

4

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

Giuliani N, Colla S, Rizzoli V. Giuliani N, et al. Among authors: colla s. Exp Hematol. 2004 Aug;32(8):685-91. doi: 10.1016/j.exphem.2004.03.015. Exp Hematol. 2004. PMID: 15308315 Free article. Review.

5

The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.

Giuliani N, Colla S, Morandi F, Rizzoli V. Giuliani N, et al. Among authors: colla s. Haematologica. 2004 Sep;89(9):1118-23. Haematologica. 2004. PMID: 15377473

6

Angiopoietin-1 and myeloma-induced angiogenesis.

Giuliani N, Colla S, Morandi F, Rizzoli V. Giuliani N, et al. Among authors: colla s. Leuk Lymphoma. 2005 Jan;46(1):29-33. doi: 10.1080/1042-8190400001022. Leuk Lymphoma. 2005. PMID: 15621778 Review.

7

Angiogenic switch in multiple myeloma.

Giuliani N, Colla S, Rizzoli V. Giuliani N, et al. Among authors: colla s. Hematology. 2004 Oct-Dec;9(5-6):377-81. doi: 10.1080/10245330400018524. Hematology. 2004. PMID: 15763977 Free article. Review.

8

Update on the pathogenesis of osteolysis in multiple myeloma patients.

Giuliani N, Colla S, Rizzoli V. Giuliani N, et al. Among authors: colla s. Acta Biomed. 2004 Dec;75(3):143-52. Acta Biomed. 2004. PMID: 15796087 Review.

9

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C, Bonomini S, Manferdini C, Codeluppi K, Facchini A, Rizzoli V. Giuliani N, et al. Among authors: colla s. Cancer Res. 2008 Aug 15;68(16):6840-50. doi: 10.1158/0008-5472.CAN-08-0402. Cancer Res. 2008. PMID: 18703490

10

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, Todoerti K, Agnelli L, Neri A, Rizzoli V, Giuliani N. Abeltino M, et al. Among authors: colla s. Exp Hematol. 2011 Jan;39(1):55-65. doi: 10.1016/j.exphem.2010.10.005. Epub 2010 Oct 25. Exp Hematol. 2011. PMID: 20977926

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

122 results

Search Page

Filters